Search bioRxiv⌕ Search

bioRxiv · 10.1101/2024.11.18.624056

Profiling amino acid substitution on proteomic scale unveils novel protein regulation in cancer diseases

Abstract

Amino acid (AA) substitutions play a critical role in regulating cellular activities, including complex signaling and cell cycle processes. Recent research on AA substitutions has primarily relied on genomic and transcriptomic data. The identification at the proteomic scale remains underexplored, despite evidence suggesting that DNA and RNA biosynthesis are not the sole sources of these substitutions. This gap persists due to challenges in analyzing large-scale proteomic data. In this study, we address this limitation by analyzing multiple independent datasets across five cancer types using PIPI-C, a novel mass spectrometry data analysis tool. And we propose AA substitutomics, a pipeline for characterizing AA substitutions arising after protein translation and dissecting the regulatory functions of key proteins with AA substitutions. Among our identified AA substitutions, 87% are novel findings and not recorded in genomic/transcriptomic databases, which indicates that the post-translational AA substitutions are prevalent. Our findings reveal biologically significant AA substitutions linked to cancer, such as F43S and E91D in hemoglobin subunit beta, P584T in filamin A, and A175N in fructose-bisphosphate aldolase B. Furthermore, our pipeline enables direct investigation of drug resistance and immune escape. By capturing functional protein-level alterations beyond genomic and transcriptomic profiling, it establishes a robust framework to advance cancer research.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Zhao, P., DAI, S., Lai, S., Zhou, C., Yu, W., Li, N.. 2024-11-19. Profiling amino acid substitution on proteomic scale unveils novel protein regulation in cancer diseases. https://doi.org/10.1101/2024.11.18.624056

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Sisyphus at the splenic flexure: sidedness in colorectal cancer

Colorectal cancer is divided into left and right to guide prognosis and therapy, yet a precise definition of left vs right sided colorectal cancer is still not fully agreed upon. The published conventions place it anywhere between the cecum and the rectosigmoid junction. The dichotomy assumes side homogeneity, i.e., that colorectal subsites within a side add limited information once the side is known. That assumption has been examined primarily through mutation prevalence, a quantity that confounds how often a driver arises with how strongly it is selected once it has. Analyzing 1,027 whole-exome and whole-genome sequenced colorectal tumors, we decomposed the prevalence of six driver groups into mutation supply and cancer effect, and asked whether a binary side label captures how each of their prevalence, mutation supply, and cancer effect vary along the colorectum. Mostly it does: the mutational input behaves as two blocks, and even the more than thirty-fold strengthening of cancer effect on BRAF V600E from sigmoid colon to cecum is adequately captured by side. But APC shows nominal evidence against side homogeneity in both prevalence and cancer effect while showing little net left-right difference, and PIK3CA H1047 rejects it in supply. The evidence for finer resolution is real but partial, and the failures do not announce themselves. We recommend additional research recording primary tumor location at the finest practicable resolution--at minimum, International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3) topography. Such well-annotated datasets would enable the left-right boundary to be a reversible analytic choice rather than an irreversible annotation.

cancer biology↗

GATA2 SUMOylation Regulates GATA2 Stability to Control Uterine Serous Carcinoma Invasion

Uterine serous carcinoma (USC) is an aggressive uterine cancer subtype that rapidly invades the uterine myometrium and is responsible for 40% of uterine cancer deaths. The molecular mechanisms that underlie this aggressive phenotype are poorly understood. We reported recently that USC tumors with low expression of the zinc-finger transcription factor GATA Binding Protein 2 (GATA2) exhibit aggressive tissue invasion, while retention of GATA2 expression is an independent predictor of 100% recurrence-free and cancer-specific survival in patients with early-stage USC. Here, we explored the mechanism of GATA2 loss in USC tumors that portend invasion. We show that GATA2 in human USC cell lines has a rapid 128-minute protein half-life due to post-translational SUMOylation, which targets GATA2 for ubiquitin-dependent proteasomal degradation. Treatment with small-molecule SUMOylation inhibitors, siRNA-mediated depletion of SUMO-2/3, or mutation of GATA2 K222 and K389 increases GATA2 levels and suppresses invasion in USC cell lines and USC tumor spheroids without impacting cell proliferation or viability. Primary USC tumors from newly diagnosed patients show markedly increased SUMO-2/3 levels and upregulation of SUMOylation pathways compared to other uterine cancer subtypes or benign endometrium, and heat-shock mediated induction of USC SUMO signaling leads to a SUMOylation-dependent reduction in GATA2 levels. Our results implicate SUMOylation as a dynamic regulator of USC GATA2 levels and support a model in which stress-related increases in SUMO activity deplete GATA2 to drive USC invasion. Our findings also raise the possibility that small-molecule SUMOylation inhibitors may benefit patients with early-stage USC disease.

cancer biology↗

SLC25A39 loss disrupts mitochondrial redox homeostasis and exposes therapeutic vulnerabilities in glioblastoma

Glioblastoma is an incurable brain tumour characterised by extensive hypoxia and phenotypic plasticity, both of which drive therapy resistance. Mitochondrial glutathione, dependent on the inner membrane carrier SLC25A39, is central to buffering the oxidative stress that hypoxia generates; its regulation and significance in glioblastoma are nonetheless unknown. We find that SLC25A39 expression is hypoxia-inducible and HIF-dependent, enriched in hypoxic tumour niches and heterogeneously expressed within and between tumours. Its loss depletes mitochondrial glutathione, causing oxidative damage to nucleic acids and lipids, mitochondrial hyperfusion, impaired respiration and a compensatory shift towards glycolysis, glutamine catabolism and serine synthesis. SLC25A39-deficient cells grow poorly, yet resist temozolomide while becoming markedly sensitive to navitoclax, an inhibitor of Bcl-2 and Bcl-xL, which increases cell killing when combined with radiation and temozolomide. In this work, we identify SLC25A39 as a metabolic vulnerability and candidate stratification marker in glioblastoma.

cancer biology↗